VNERi: A Superior Hemodynamic Marker in Early Septic Shock

Study Background and Research Question

Septic shock represents one of the most challenging syndromes in critical care, marked by profound abnormalities in vascular tone and hemodynamics. Loss of vasomotor tone, largely due to vascular hyporesponsiveness to adrenergic agonists such as norepinephrine, underpins persistent hypotension and tissue hypoperfusion. Traditional bedside markers—including diastolic arterial pressure (DAP), the DAP/heart rate (HR) ratio, and mean arterial pressure (MAP)—are commonly used to guide vasopressor therapy, but their ability to directly reflect vascular responsiveness remains limited. The recent study by Goury et al. sought to address this gap by proposing a new composite index (VNERi) that integrates DAP, HR, and norepinephrine dose, aiming to provide a more reliable indicator of vascular responsiveness and its prognostic significance in early septic shock.

Key Innovation from the Reference Study

The central innovation of the Goury et al. study is the introduction and validation of the Vascular NE Responsiveness Index (VNERi), mathematically defined as DAP/(NE dose × HR), where the norepinephrine dose is standardized in μg/kg/min using the bitartrate formulation. Unlike previous indices that considered DAP or DAP/HR alone, VNERi explicitly accounts for the amount of exogenous vasoconstrictor required to maintain a given diastolic pressure at a particular heart rate, thus isolating a patient's vascular reactivity from confounding factors such as tachycardia or sedative use. This approach is physiologically grounded, recognizing that vasomotor tone and vascular responsiveness are related but distinct phenomena in septic shock pathophysiology.

Methods and Experimental Design Insights

Goury et al. conducted a post-hoc analysis utilizing the well-characterized ANDROMEDA-SHOCK database, encompassing 424 patients with early septic shock. Hemodynamic variables—including DAP, HR, and initial norepinephrine dose (expressed in μg/kg/min, bitartrate formulation)—were collected within four hours of shock diagnosis and randomization. The selection of standardized dosing and the specific use of the Norepinephrine bitartrate formulation aligns with recent recommendations for consistent reporting in critical care research. Multivariate analyses were employed to evaluate associations between candidate hemodynamic indices (DAP, DAP/HR, MAP/NE dose, and VNERi) and clinically meaningful outcomes: in-hospital mortality, vasopressor-free days, and renal replacement therapy (RRT)-free days up to 28 days post-inclusion.

Protocol Parameters

• Hemodynamic data collection: Record DAP, MAP, HR, and NE dose (μg/kg/min, bitartrate formulation) within 4 hours of septic shock diagnosis.
• NE dosing standardization: Express all norepinephrine doses in μg/kg/min, specifying the salt form (bitartrate) for cross-study comparability (read more).
• VNERi calculation: Compute VNERi as DAP divided by (NE dose × HR); use for risk stratification and bedside assessment.
• Outcome tracking: Monitor in-hospital mortality, vasopressor-free days, and RRT-free days over 28 days.

Core Findings and Why They Matter

The study found that VNERi displayed the strongest independent association with in-hospital mortality when compared to DAP, DAP/HR, and MAP/NE dose. Specifically, an inverted J-shaped relationship was observed: patients with VNERi below 6.7 experienced markedly increased mortality. This threshold also correlated with fewer vasopressor-free and RRT-free days, highlighting the clinical relevance of impaired NE responsiveness. Importantly, VNERi provided a more nuanced stratification of patients’ vascular status, offering actionable guidance for therapeutic escalation (e.g., increasing NE dose versus introducing adjunct vasopressors). By leveraging the physiological determinants of DAP and standardizing for HR and NE dose, VNERi advances the field beyond traditional static markers, grounding decision-making in a robust, patient-specific index. These findings have immediate implications for bedside practice and future clinical trial design.

Comparison with Existing Internal Articles

Several internal articles contextualize the impact and translational opportunities of this new index. A recent review summarizes VNERi’s development and underscores its outperformance of traditional hemodynamic markers for prognostication in septic shock, echoing the core conclusions of Goury et al. For preclinical and translational researchers, guidance on the deployment of (-)-Norepinephrine (+)-bitartrate delves into best practices for dosing and modeling adrenergic signaling. Meanwhile, a position paper recommends standardizing norepinephrine formulation reporting, which aligns with the rigorous methodology in the reference study. Collectively, these articles create a bridge from clinical insights to experimental rigor, facilitating reproducibility and cross-study harmonization in both clinical and preclinical domains.

Limitations and Transferability

While Goury et al. demonstrate the prognostic superiority of VNERi in a large, multicenter cohort, several limitations should be acknowledged. First, the analysis is retrospective, and the index’s predictive validity requires prospective validation and external replication. Second, the study population is restricted to patients with early septic shock treated with NE, limiting immediate generalizability to other vasopressors or later phases of shock. Third, NE dosing was standardized to the bitartrate salt, which may differ in practice from other formulations; this highlights the ongoing need for harmonized reporting to ensure transferability across research and clinical settings. Finally, while VNERi accounts for key hemodynamic variables, it does not capture all covariates influencing vascular tone, such as patient-specific pharmacodynamics or concurrent medications.

Research Support Resources

Researchers aiming to model adrenergic receptor signaling, blood pressure regulation, or to induce animal models of cardiomyopathy can utilize (-)-Norepinephrine (+)-bitartrate (SKU C8723) as a validated adrenergic agonist in preclinical studies. The compound’s well-characterized receptor profile and formulation consistency support both in vitro and in vivo experimental workflows, as detailed in the internal dossier. For clinical translation or advanced cardiovascular research, referencing NE dosing as μg/kg/min (bitartrate) as in Goury et al. will facilitate methodological alignment and reproducibility. APExBIO C8723 is suitable for research use only and should be handled according to established storage and preparation guidelines.